Jennison Associates’s Sage Therapeutics SAGE Stock Holding History

Jennison Associates’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-50,000	Closed	-$4.79M	–	681
2018 Q4	$4.79M	Buy	+50,000	New	+$5.72M	0.01%	484

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Jennison Associates's SAGE Position: Q3 2021 in Review

Jennison Associates sold out of Sage Therapeutics (SAGE) in Q3 2021, closing a stake of 582,120 shares — an estimated $33.1M sold.

Jennison Associates first reported a position in SAGE in Q4 2015 and held it in 23 quarters. The position peaked at $541M in Q2 2019. 225 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

Jennison Associates reported no remaining Sage Therapeutics position as of Q3 2021 after selling out during the quarter.
Jennison Associates sold 582,120 Sage Therapeutics shares in Q3 2021, an estimated $33.1M.
Jennison Associates first reported a position in Sage Therapeutics in Q4 2015 and held it in 23 quarters.
Jennison Associates's Sage Therapeutics position peaked at $541M in Q2 2019.
225 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on Jennison Associates's 13F filing for Q3 2021, filed 9 Nov 2021.